Soleno Therapeutics Inc

Soleno Therapeutics’ insider sales and trading halt amid its $53‑per‑share merger with Neocrine reveal a strategic liquidity move, not panic, but raise short‑term liquidity and dilution risks that investors should watch closely as the deal’s value‑a…

Soleno Therapeutics insider sales reveal a tax‑management strategy rather than a warning sign, highlighting executive confidence amid drug launch and legal challenges.

Soleno Therapeutics’ CFO’s fresh insider purchase of shares and warrants shows executive confidence amid a steep stock drop, hinting at upcoming clinical milestones and partnership wins that could revive investor sentiment.